(Total Views: 348)
Posted On: 10/28/2017 6:05:51 PM
Post# of 72443
Just saw Eucrisa's commercial for eczema. It works by inhibiting the PDE4 enzyme. Eczema occurs when PDE4 enzymes are overactive in skin cells which leads to skin inflammation. We learned that B inhibits the PDE4 enzyme, no wonder IPIX is going after the eczema market.
"Brilacidin, modeled (pdf) on defensins, has been shown not only to reduce pro-inflammatory cytokines and chemokines, alongside exhibiting robust antimicrobial activity (see the images at bottom below), but also to inhibit PDE4, which is being advanced as a novel therapeutic approach in the treatment of IBD."
http://www.ipharminc.com/new-blog/2017/10/24/...el-disease
"Certain aspects of Brilacidin’s Mechanism of Action (MOA) as a defensin-mimetic may make it well-suited to treat Atopic Dermatitis (AD) (eczema) as a topical medication (formulation planning is underway), including its anti-bacterial properties as well as how it may also function to help restore balance in the skin microbiome."
http://www.ipharminc.com/new-blog/2017/6/21/t...dermatitis
"Brilacidin, modeled (pdf) on defensins, has been shown not only to reduce pro-inflammatory cytokines and chemokines, alongside exhibiting robust antimicrobial activity (see the images at bottom below), but also to inhibit PDE4, which is being advanced as a novel therapeutic approach in the treatment of IBD."
http://www.ipharminc.com/new-blog/2017/10/24/...el-disease
"Certain aspects of Brilacidin’s Mechanism of Action (MOA) as a defensin-mimetic may make it well-suited to treat Atopic Dermatitis (AD) (eczema) as a topical medication (formulation planning is underway), including its anti-bacterial properties as well as how it may also function to help restore balance in the skin microbiome."
http://www.ipharminc.com/new-blog/2017/6/21/t...dermatitis
(2)
(0)
Scroll down for more posts ▼
